BMO Capital Maintains Outperform on Disc Medicine, Raises Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan Seigerman maintains an Outperform rating on Disc Medicine (NASDAQ:IRON) and raises the price target from $40 to $70.
June 12, 2023 | 1:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital maintains an Outperform rating on Disc Medicine and raises the price target from $40 to $70.
The raised price target by BMO Capital from $40 to $70 indicates a positive outlook for Disc Medicine's stock. The Outperform rating suggests that the analyst expects the stock to outperform the market in the short term. This news is likely to have a positive impact on the stock price as it reflects increased confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100